SEARCH

SEARCH BY CITATION

References

  • 1
    Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:34813485.
  • 2
    Yanada MG-MG, Borthakur G, Ravanadi F, et al. Relapse and death during first remission in acute myeloid leukemia. Haematologica 2008;4:633634.
  • 3
    Walter RBOM, Borthakur G, Ravandi F, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment. J Clin Oncol 2011;29:44174423.
  • 4
    Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given “intensive” induction regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). ASH Annual Meeting Abstracts, 2012. 120:129.
  • 5
    Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996;87:49794989.
  • 6
    Patel JP, Gönen M, Figueroa ME, et al. “Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia.” New England J Med 2012;366:10791089.
  • 7
    Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:8989.
  • 8
    Döhner H, Estey EH, Sergio A, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453474.
  • 9
    Mrozek K, Marcucci G, Nicolet D, et al., Prognostic significance of the European leukemianet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012;30:45154523.
  • 10
    Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:41734179.
  • 11
    Marcucci G, Maharry K, Metzeler K, et al. The clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol, in press.
  • 12
    Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:74737478.
  • 13
    Bertoli SBE, Huguet F, Huynh A, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood, in press.
  • 14
    Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial. Blood 2012;120:28262835.
  • 15
    Andersson C, Li X, Lorenz F, et al. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia. Diagn Mol Pathol 2012;21:225233.
  • 16
    Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332341.
  • 17
    Walter RB, Gooley TA, Wood B, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29:11901197.
  • 18
    Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012;120:468472.
  • 19
    Rossi G, Minervini MM, Carella AM, et al. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leukemia Res 2012;36:401406.
  • 20
    Paietta E. American Society of Hematology Education Program; Minimal residual disease in acute myeloid leukemia coming of age: 2012, p. 35.
  • 21
    Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010;11:543552.
  • 22
    Petersdorf S, Kopectcy K, Stuart R, et al. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts), 2009, 114.
  • 23
    Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial. J Clin Oncol 2010;29:369377.
  • 24
    Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:39243931.
  • 25
    Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 2012;379:15081516.
  • 26
    Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: Time to resurrect? J Clin Oncol 2012;30:39213923.
  • 27
    Estey E. Treatment of AML: Resurrection for gemtuzumab ozogamicin? Lancet 2012;379:14681469.
  • 28
    Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:12481254.
  • 29
    Estey EH, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:34693473.
  • 30
    Lo-Coco F, Avvisati G, Orlando SM, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): Results of the phase III, prospective, randomized, intergroup APL0406 study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. ASH Annual Meeting Abstracts 2012;120:6.
  • 31
    Cortes JE, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >= 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. ASH Annual Meeting Abstracts 2012;120:48.
  • 32
    Levis MJ, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. ASH Annual Meeting Abstracts 2012;120:673.
  • 33
    Smith CC, Lasater E, Mccreery M, et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance-causing FLT3 kinase domain mutants. ASH Annual Meeting Abstracts 2012;120:141.
  • 34
    Rollig C, Muller-Tidow C, Huttmann A, et al. Sorafenib versus placebo in addition to standard therapy in adult patients >=60 years with newly diagnosed acute myeloid leukemia: Results from the randomized-controlled soraml trial. ASH Annual Meeting Abstracts 2012;120:144.
  • 35
    Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial. J Clin Oncol 2013;30:24922499.
  • 36
    Burnett AK, Russell NH, Kell J, et al. A comparison of daunorubicin/Ara-C (DA) versus daunorubicin/clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: Results of the UK NCRI AML16 Trial. ASH Annual Meeting Abstracts 2012;120:892.
  • 37
    Burnett AK, Russell NH, McMullin MF, et al. A randomised comparison of clofarabine versus low dose Ara-C as first line treatment for older patients with AML. ASH Annual Meeting Abstracts 2012;120:889.
  • 38
    Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: A multicenter, randomized phase III study. J Clin Oncol 2012;30:24412448.
  • 39
    Appelbaum FR. Haematological cancer: The rule of three in AML induction—Is cladribine the answer? Nat Rev Clin Oncol 2012;9:376377.
  • 40
    Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2011;120:48404845.
  • 41
    Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012;30:26702677.
  • 42
    Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2009;28:562569.
  • 43
    Blum W, Sanford B, Klisovic RB, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: A Phase II cancer and leukemia group B study (CALGB 10503, Alliance). ASH Annual Meeting Abstracts 2012;120:44.
  • 44
    Schlenk RF, Herr W, Wulf G, et al. Azacitidine-containing induction regimens followed by azacitidine maintenance therapy in high risk acute myeloid leukemia: First results of the randomized phase-II AMLSG 12-09 study (ClinicalTrials.gov No. NCT01180322). ASH Annual Meeting Abstracts 120:412.
  • 45
    Kantarjian HM, Roboz GJ, Rizzieri DA, et al. Results from the dose escalation phase of a randomized phase 1–2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SQ) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML. Blood (ASH Annual Meeting Abstracts) 2012 120:Abstract 414.
  • 46
    Maertens J, Lubbert M, Fiedler W, et al. Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): Results from the randomized phase II part for volasertib in combination with low-dose cytarabine (LDAC) versus LDAC monotherapy in patients with previously untreated AML ineligible for intensive treatment. ASH Annual Meeting Abstracts 120:411.
  • 47
    Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:14871496.
  • 48
    Appelbaum FR. Pursuing the goal of a donor for everyone in need. New England J Med 2012;367:15551556.
  • 49
    Lazarus HM. Acute leukemia in adults: Novel allogeneic transplant strategies. Hematology 17:S47S51.
  • 50
    de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2010;116:54205431.
  • 51
    Platzbecker UWM, Radke J, Oelschlaegel U, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial. Leukemia 2012;26:381389.
  • 52
    Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011;364:10271036.
  • 53
    Breems DA, Wim LJ, Van Putten et al. Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:47914797.
  • 54
    Fang M, Storer B, Estey EH, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011;118:14901494.
  • 55
    Busfield SJ, Biondo M, Wong M, et al. CSL362: A monoclonal antibody to human interleukin-3 receptor (CD123), optimized for NK cell-mediated cytotoxicity of AML stem cells. ASH Annual Meeting Abstracts 2012;120:3598.